Kirsten M. Timms
Myriad (Germany)(DE)Myriad Genetics(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, BRCA gene mutations in cancer, Ovarian cancer diagnosis and treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer(2016)1,128 cited
- → Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial(2018)889 cited
- → Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer(2012)837 cited
- → Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer(2011)600 cited
- → Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next‐generation sequencing with a 25‐gene panel(2014)431 cited
- → TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer(2015)426 cited